Sign in
Taking people in United StatesPhase 1/2

Tests donor immune cell addback to prevent infections after stem cell transplant

Tests donor immune cells added back after transplant in children with leukemia or lymphoma.

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Status
Recruiting
Phase
Phase 1/2
People taking part
100 people, planned
Started
21 Mar 2025
Expected to end
Mar 2032
Type of study
Interventional, 3 groups
Treatments tested
  • Phase 1 Dose Level 1
  • Phase 1 Dose Level 2
  • Phase 1 Dose Level 3
  • Phase 2 Maximum Tolerated Dose determined in Phase 1
  • Phase 2 Established Dose from prior study, NCT03810196
Record updated
15 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people up to 25 years old with blood cancers, bone marrow failure or immune disorders who need a stem cell transplant from a donor who is not a fully matched sibling.

Age
From 1 Month to 25 Years.
Sex
All sexes can join.
Disease stage
A disease for which a donor stem cell transplant may remove the disease. Blood cancer remission status follows the transplant program's standard practice. Conditions include high risk leukemia, relapsed leukemia, MDS, relapsed non-Hodgkin lymphoma, aplastic anemia, inherited bone marrow failure and immune disorders.
Earlier treatment
No planned alemtuzumab during conditioning.
Biomarker or test result
The donor needs a tissue type test. A related donor must be at least 5/10 HLA matched. An unrelated donor must be 9/10 or 10/10.

Main reasons for not taking part

  • Performance score less than 60
  • No donor available for mobilized peripheral stem cells
  • Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma
  • Has an available 10/10 HLA matched sibling donor
  • Does not meet the center's disease, organ or infection criteria

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Disease for which allogeneic HSCT may be curative
  • Remission status of hematologic malignancies and additional disease-specific eligibility determinations will be according to standards of practice within the CHOP Cellular Immunotherapy and Transplant Program (CTTS)
  • Patients must be 25 years of age and less
  • Evaluation for organ and infectious status as per our CTTS standard operating procedure
  • Signed consent by parent/guardian or able to give consent if 18 years of age and older
  • Participants of childbearing potential must have a negative pregnancy test as per institutional SOP

Who cannot take part

  • HLA testing/matching; HLA testing to be done by molecular methods for A, B, C, DRB1, DQB1; Related donor: Must be ≥ 5/10 match; Unrelated donor: 10/10 or 9/10 match; KIR typing for haploidentical donor for hematologic malignancies; Donor specific HLA antibodies (DSA) should be assessed for all subjects receiving an HLA mismatched graft (≤ 9/10)
  • Patients who do not meet institutional disease, organ or infectious criteria; Donor selection and eligibility:
  • Patients who have performance score less than 60
  • No suitable donor available for mobilized peripheral stem cells
  • Patients with Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma
  • Planned receipt of alemtuzumab during conditioning
  • Patients with an available 10/10 HLA matched sibling donor
  • Unrelated donor meets National Marrow Donor Program criteria for donation
  • Related donor (at least haploidentical) willing and able to donate mobilized peripheral stem cells
  • Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection
  • Donors must be willing to sign consent to participate in this study

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Megan AtkinsonTaking people

About the trial

What the trial wants to find out

The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.

The 3 groups in the trial

  • Phase 1:TCRab/CD19 depleted PSCT with CD45RA depleted addback using mismatched related donors (MMRD)Treatment being tested

    Stem cell source: mobilized peripheral blood stem cells (PBSC) Donor type: \> or = 5/10 mismatched related donor Conditioning: disease specific standard of care (SOC) regimens

    Treatment: Phase 1 Dose Level 1, Phase 1 Dose Level 2, and Phase 1 Dose Level 3

  • Phase 2:TCRab/CD19 depleted PSCT with CD45RA depleted addback at MTD found in phase 1 using MMRDTreatment being tested

    Stem cell source: mobilized PBSC Donor type: \> or = 5/10 mismatched related donor Conditioning: disease specific SOC regimens

    Treatment: Phase 2 Maximum Tolerated Dose determined in Phase 1

  • Phase 2:TCRab/CD19 depleted PSCT with CD45RA depleted addback using unrelated donorsTreatment being tested

    Stem cell source: mobilized PBSC Donor type: 9/10 or 10/10 matched unrelated donor Conditioning: disease specific SOC regimens

    Treatment: Phase 2 Established Dose from prior study, NCT03810196

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant
Plain-language title
Tests donor immune cell addback to prevent infections after stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 April 2026